Overall survival for amivantamab plus lazertinib vs osimertinib in Asian participants with first-line EGFRmutant advanced NSCLC: MARIPOSA subgroup analysis

Hayashi, H.; Kim, Y. J.; Lee, S-h.; Danchaivijitr, P.; Liu, B.; Alip, A.; Xiong, H.; How, S. H.; Chang, G-c.; Yang, J. c-h.; Yoshioka, H.; Sendur, M. A. N.; Prabhash, K.; Azuma, K.; Akawung, A.; Fennema, E.; Shah, S.; Sethi, S.; Cho, B. C.; Lu, S.

doi:10.1016/j.annonc.2025.10.684

상세 보기

Overall survival for amivantamab plus lazertinib vs osimertinib in Asian participants with first-line EGFRmutant advanced NSCLC: MARIPOSA subgroup analysis

Hayashi, H.;
Kim, Y. J.;
Lee, S-h.;
Danchaivijitr, P.;
Liu, B.;
외 15명

Citations

WEB OF SCIENCE

0

Citations

SCOPUS

0

제목: Overall survival for amivantamab plus lazertinib vs osimertinib in Asian participants with first-line EGFRmutant advanced NSCLC: MARIPOSA subgroup analysis

저자: Hayashi, H.; Kim, Y. J.; Lee, S-h.; Danchaivijitr, P.; Liu, B.; Alip, A.; Xiong, H.; How, S. H.; Chang, G-c.; Yang, J. c-h.; Yoshioka, H.; Sendur, M. A. N.; Prabhash, K.; Azuma, K.; Akawung, A.; Fennema, E.; Shah, S.; Sethi, S.; Cho, B. C.; Lu, S.

DOI: 10.1016/j.annonc.2025.10.684

발행일: 2025-12

유형: Meeting Abstract

저널명: Annals of Oncology

권: 36

ScholarWorks@성균관대학교

상세 보기